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Abstract
Effect of KCC2-enhancing prodrug CLP290 on Tat ± morphine treated female mice
at the behavioral and molecular levels
A dissertation submitted in partial fulfillment of requirements for the degree of Master of
Science at Virginia Commonwealth University
By
Michael Marone
Bachelor of Science, University of South Carolina
Major Director: Dr. Kurt Hauser
Professor, Department of Pharmacology and Toxicology

HIV-1 infection is highly comorbid with opioid use disorder. Prescription and illicit use of
opioids are particularly risky for HIV-1 infected individuals due to potential synergistic
neurotoxic effects mediated by viral proteins and opioids. Additionally, opiate drug abuse
has been shown to exacerbate neuropathogenesis of HIV-1+ individuals. Development of
combination antiretroviral therapies (cART) has drastically improved the life expectancy
of these patients. Unfortunately, although the severity of neurological and neurocognitive
complications has declined, the incidence of HIV-associated neurocognitive disorders
(HAND) remains 30-50% in the post-cART era and is worsened by opioid use disorder.
HIV-1 proteins, inflammatory mediators, and excitotoxins released and recruited by
infected cells lead to sublethal neuronal pathologies, providing the neural basis of HAND.
The striatum is a central interface for locomotor and addiction circuits that becomes
dysregulated by opioids and is susceptible to harboring high viral loads leading to marked
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neuropathology in HIV infected individuals. While neurons cannot be infected with HIV,
glial cells, such as astrocytes, are preferentially targeted and are the source of many
sublethal neuronal effects associated with HAND. While it has been demonstrated HIV
viral protein, Tat, is synergistically excitotoxic with morphine through an NMDA receptormediated manner, little is known about how HIV-1 Tat interacts with opioids on
GABAergic systems. The studies in this dissertation use a glial fibrillary acidic protein
(GFAP)-driven doxycycline (DOX)-inducible Tat-transgenic model in female mice that
accurately mimics neurological deficits in people living with HIV (PLWH).
Previous studies using this model in male mice showed diminished levels of K+ Cl−
cotransporter 2 (KCC2) a neuron specific cotransporter that is essential for maintaining
low levels of intracellular Cl- required for proper GABAAR-mediated hyperpolarization.
Additionally, loss of overall KCC2 levels and KCC2 membrane localization via decreased
phosphorylation of Serine 940-KCC2 were rescued by oral gavage of KCC2-enhancing
prodrug CLP290. We performed similar studies in female DOX-inducible Tat-transgenic
mice and administered a ramping dose of morphine to understand the interactive effects
with Tat. We found that morphine administration increased anxiety-related behavior and
decreased exploration in an open field test. Using western blot analysis to reveal potential
changes in expression levels, we found CLP290 increased overall KCC2 levels in the
striatum but had no effect on p940-KCC2 or on the immature neuron cotransporter Na-K2Cl cotransporter 1 (NKCC1). Interestingly, we found that Tat and CLP290 independently
diminished levels of calcium-activated chloride channel TMEM16a, suggesting an
alternative mechanism where Tat may dysregulate intracellular Cl-. Overall, these studies
demonstrate a potential sex difference in the effects of this Tat-transgenic model and
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CLP290 on KCC2 that should be further investigated in side-by-side studies to better
understand KCC2 as a prospective treatment target for HAND and opiate use.
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Chapter 1: Introduction
Human immunodeficiency virus (HIV)
In 2020 there were 37.7 million PLWH with 1.5 million new HIV infections during
this year alone (UNAIDS 2021). HIV is in the lentivirus genus within the retrovirus
subfamily and can be classified as HIV-1 or HIV-2 subtypes. HIV-1 is the canonical
subtype associated as HIV and is divided into M, N, O, and P strains with M viruses being
the responsible for a majority of global HIV-1 infections since the emergence of the HIV
pandemic (Bbosa, Kaleebu, & Ssemwanga, 2019). HIV is diagnosed by quantifying the
number of cluster of differentiation (CD) CD4+ T-cells in patient plasma samples which
determines the level of immunodeficiency. Upon diagnosis, measurement scores of
plasma viral load, CD4+ count, and clinical indicators are used as criteria for planning of
anti-retroviral therapy (ART) (Simon, Ho, & Karim, 2006).

HIV viral entry and life cycle
There are three main steps during HIV entry sequence which consists of CD4
binding, co-receptor binding, and membrane fusion/cell entry. The HIV-1 lipid bilayer
envelope contains the integral membrane glycoprotein (gp)160 that is comprised of gp120
and gp41, which are responsible for attachment to host cells, primarily CD4+ T-cells and
macrophages. CD4 receptor binding leads to conformational changes in gp120 variable
loops, particularly the V3 loop, which is critical to C-C chemokine receptor 5 (CCR5) or
C-X-C chemokine receptor type 4 (CXCR4) co-receptor binding. Viruses that utilize a
particular coreceptor are termed R5- or X4-tropic viruses, respectively (Wilen, Tilton, &
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Doms, 2012). Upon co-receptor binding, a conformational changes in gp41 allows for
viral-host membrane fusion and subsequent viral insertion into the host cell (Doms &
Moore, 2000; Wilen et al., 2012). Understanding of the viral entry process and tropism of
HIV-1 has led to the development of more effects ARTs. For example, ART drugs have
been developed to block multiple stages of the viral entry process in attachment inhibitors
that prevent HIV-CD4 interaction, CXCR4 and CCR5 coreceptor inhibitors, and fusion
inhibitors which inhibit virus and cell membrane attachment (Lobritz, Ratcliff, & Arts,
2010). Once inside the host cell, HIV hijacks host cell machinery to produce low levels of
viral transcript. One of the first viral proteins produced is trans-activator of transcription
(Tat). Tat enhances viral replication by binding the TAR region of new transcripts as well
as recruiting transcriptional proteins for more efficient replication (Bannwarth & Gatignol,
2005; Das, Harwig, & Berkhout, 2011).

HIV-associated neurocognitive disorders
The spectrum of neurocognitive impairments associated with HIV-1 infection are
termed HIV-associated neurocognitive disorders (HAND). This spectrum ranges from the
mildest form in asymptomatic neurocognitive impairment (ANI) to the most severe form
in HIV-associated dementia (HAD). While PLWH need impairment in 2 or more
neurocognitive domains to be diagnosed with HAND, people with HAD need to show
marked impairment in daily life as opposed to people with ANI show no impairment in
daily life. People affected by HAND classically present with memory impairment,
executive dysfunction, lack of impulse control, emotional dysregulation, and motor
impairments (Saylor et al., 2016; Antinori et al., 2007).
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Viral entry into the brain and CNS can be detected early after infection. This was
initially shown though synthesis of HIV antibodies within the blood-brain barrier (BBB)
and isolation of the virus from cerebrospinal fluid (CSF) of asymptomatic HIV-patients
(Gendelman et al., 1989). While still under debate, the predominant theory describing HIV
entry into the brain is the “Trojan Horse” hypothesis in which dendritic cells (DCs)
endocytose and harbor pathogens, including HIV, and in vitro evidence suggests DCs
transmit virions to neighboring T-cells via exocytosis (Cavrois, Neidleman, & Greene,
2008). HIV is thought to enter the brain concealed within infected CD4+ monocytes and
macrophages across the BBB (Bock, Zhai, Sharer, Mccomb, & Swindells, 2021; Jaeger
& Nath, 2012). While neurons do not become infected with HIV, virus is detected in
perivascular macrophages, parenchymal microglia, and astrocytes of the brain
(Thompson, Cherry, Bell, & McLean, 2011). Infection of resident microglia and astrocytes
leads to glial activation and cell specific effects to function and morphology.

Opiates, HIV, and the Striatum
The United States is in the midst of an opioid drug epidemic with over 1.6 million
people having opioid use disorder (OUD) and 70,000 deaths from opioid overdoses
(“About the Epidemic | HHS.gov,” n.d.). Morphine, isolated from opium in 1806, is one of
the most potent and readily prescribed analgesic drugs used today but has strong abuse
potential (Brownstein, 1993; Darcq & Kieffer, 2018). Discovering that opioids such as
morphine bind to endogenous opioid receptors in the brain unlocked an era of research
to understanding the analgesic and addictive properties of opioids. Opioids mimic the
endogenous opioid system by binding the µ (MOR), k (KOR), and δ (DOR) opioid
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receptors. These G-protein coupled receptors (GPCRs) are distributed throughout the
CNS and mediate analgesia, addiction, emotion, and stress responses (Benarroch,
2012). The most extensive studied of these receptors is the MOR, which is highly
expressed in the midbrain. Activation of MOR classically inhibits GABAergic neurons of
the ventral tegmental area (VTA) via Gi/o signaling. This leads to disinhibition of
downstream dopaminergic neurons and subsequent increased dopamine release within
the nucleus accumbens (NAc). Hijacking of this mesolimbic dopamine circuit has long
been implicated behind the development of addictive behaviors (Koob & Volkow, 2010;
Lobo & Nestler, 2011; Yager, Garcia, Wunsch, & Ferguson, 2015).
There are extensive findings describing that prescription or illicit use of opiate
drugs can worsen the HIV neuropathology mediated by viral proteins and opioids. Opiates
accelerate the pathogenesis of HIV-1 infection and worsen neurological outcomes
through direct interactions in the central nervous system (CNS) (Chang & Connaghan,
2012; Hauser, Fitting, Dever, Podhaizer, & Knapp, 2005; Reddy, Pilakka-Kanthikeel,
Saxena, Saiyed, & Nair, 2012). While development of combination antiretroviral therapies
(cART) has drastically improved the life expectancy of patients, neurocognitive disorders
still affect 30-50% of HIV+ individuals (Heaton et al., 2010; Saylor et al., 2016). Morphine
can modulate various levels of HIV infection, viral entry, inflammation, and alter levels of
HIV-1 coreceptors CCR5 and CXCR4 (Guo et al., 2002; Rogers, 2020; Sengupta et al.,
2009). Morphine can potentiate HIV-1 replication and viral entry in neonatal monocytederived macrophages (Li et al., 2003). Morphine and HIV-1 Tat can work alone and in a
synergistic fashion to decrease blood-brain barrier (BBB) integrity, decrease transendothelial electric resistance, decreasing expression of tight junction proteins, and
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increase trans-migration of PBMCs across an in vitro BBB ( Mahajan et al., 2008; Williams
et al., 2014)
Particular brain regions are more vulnerable to the effects of HIV infection. The
striatum is a central interface for motor, reward, and addiction circuits, which can become
disrupted by drugs of abuse and is profoundly affected by HIV (Du Plessis et al., 2014;
Zhou et al., 2009). Synergistic neurotoxic effects of HIV-1 and opioids on neurons are
primarily mediated by mu-opioid receptor (MOR) expressing glia (S. Kim et al., 2018; Zou
et al., 2011).Infected macrophages, microglia, and affected astrocytes can release viral
proteins such as trans-activator of transcription (Tat) and envelope glycoprotein gp120.
Tat and gp120 are contributors to HIV-1 induced synaptodendritic damage and cell death.
Loss of synaptic connectivity and dendritic arborization are likely substrates of cognitive
impairment in HAND (E, Masliah, N, Ge, M, Morey, R, DeTeresa, RD Terry, 1992; Eliezer
Masliah et al., 1997b), as well as opiate-HIV interactive deficits in CNS structure and
function (Anthony, Arango, Stephens, Simmonds, & Bell, 2008; E, Masliah, N, Ge, M,
Morey, R, DeTeresa, RD Terry, 1992; Fitting et al., 2010; Sá et al., 2004).

Neuronal dysfunction in HAND
Behavioral and cognitive deficits in HAND are likely due to reduced dendritic
arborization and synaptic degeneration (Eliezer Masliah et al., 1997a). While HIV does
not directly infect neurons, HIV-viral proteins released by glial cells such as Tat and gp120
have direct effects on neurons. Striatal neurons exposed to Tat in vitro and in vivo show
reduced dendritic length, reduced number of dendritic spines, total dendrite number, as
well as increased dendritic swelling and varicosities (Fitting et al., 2014, 2010; Irollo,
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Luchetta, Ho, Nash, & Meucci, 2021; Y. Liu et al., 2018). This is likely due to Tat-induced
direct and indirect excitotoxic mechanisms. HIV-1 Tat has an affinity for the N-methyl-Daspartate receptor (NMDAR) and has been shown increase NMDAR activation,
expression, and glutamate release (Eugenin et al., 2011; Haughey, Nath, Mattson, Slevin,
& Geiger, 2001; Hu, 2016). Tat-induced activation of NMDARs leads to prolonged and
elevated levels of intracellular Ca2+ in striatal neurons in both the cytoplasm and dendrites.
In addition to NMDAR-mediated Ca2+ influx, downstream signaling through ryanodine
receptors causes release of intracellular Ca2+ from endoplasmic reticulum (ER) internal
stores. Internal stores alone have been shown to be a large supply of excessive
intracellular calcium in neurons in vitro where calcium levels and elevation of striatal
neurons in calcium-free mediate in the presence of Tat are no different than with calciumcontaining medium (Fitting et al., 2014). Tat-mediated excessive calcium influx and
internal release both contribute to excitotoxic damage behind neuronal cell death and
dendritic damage.
While overactivation of excitatory ions and signaling have been shown as a strong
contributor to neuronal dysfunction in HAND, recent evidence is elucidating the
importance of inhibitory signaling. Autopsy studies from HIV-infected individuals display
highly significant alterations in GAD1 and GABRA1 (Buzhdygan et al., 2016; Gelman,
Chen, et al., 2012) involved in GABAergic neurotransmission that rival alterations in
genes involved in glutamate transmission (Gelman, Lisinicchia, et al., 2012).

Tat-

expressing transgenic mouse show a selective loss of reductions in somatostatinimmunopositive

(SOM+)/neuropeptide

Y-immuno-negative

(NPY−),

parvalbumin-

immunopositive (PV+), and neuronal nitric oxide synthase-immunopositive (nNOS+)
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GABAergic interneurons in hippocampal area CA1 (Marks et al., 2016) and a loss of
inhibitory postsynaptic currents in ex vivo slices (Xu & Fitting, 2016). Interestingly, the
loss of GABAergic markers does not appear to be accompanied by the loss of GABAergic
neurons, suggesting alterations to GABAergic function at the molecular level (Buzhdygan
et al., 2016; E. Masliah, Achim, Hansen, & Wiley, 1992). Thus, selective deficits in
GABAergic function and neuronal markers suggests the preferential loss of inhibitory
function may underlie the apparent increases in excitotoxicity in HIV-related neuronal
dysfunction.
Neuronal chloride regulation and GABAergic function
Vulnerability of inhibitory signaling in HIV has been shown through reduction in the
expression of GABAergic markers and frequency and amplitude of IPSCs. Additionally,
studies investigating other neurodegenerative diseases are also finding disruptions to
GABAergic machinery, showing the delicate nature of inhibitory signaling regulation
(Akbarian et al., 1995; Lanoue, Dumitriu, Myers, & Soghomonian, 2010; Volk, Austin,
Pierri, Sampson, & Lewis, 2000). GABAergic signaling is highly dependent upon
intracellular ([Cl−]i) homeostasis to allow proper GABAergic inhibition. Minor changes in
[Cl−]i can dramatically affect the strength and polarity of inhibitory GABAA receptor
function (De Koninck, 2007). Slight increases in [Cl−]i (as little as 5 mV) can shift the Cl−
equilibrium potential (ECl) (Prescott, Sejnowski, & De Koninck, 2006), and reverse the
polarity of GABAA currents—such that an inhibitory transmitter signal can be excitatory
(Chamma, Chevy, Poncer, & Lévi, 2012; De Koninck, 2007). Unlike glutamate in
excitatory neurotransmission, GABA function changes over the course of development
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as well as shifts in the [Cl−]i gradient (Ben-Ari, Khalilov, Kahle, & Cherubini, 2012). To
understand the role of Cl− regulation in HIV-mediated disruptions to GABAergic
transmission, we investigated into several candidate Cl− regulating channels (KCC2,
NKCC1, and TMEM16A) that will be discussed further.
NKCC1 and KCC2:

The hyperpolarizing nature of GABA relies on a gradient with low levels in
intracellular Cl- allowing for rapid Cl- influx and hyperpolarization upon GABA receptor
(GABAR) binding. The dichotomic nature of GABA signaling over the course of
development is due to dynamic changes in the expression and function of neuronal
neurotransmitter receptors, ion channels, and transporters (Ben-Ari et al., 2012; Chamma
et al., 2012). The Cl- gradient during development is primarily driven by the Na+-K+- 2Clcotransporter NKCC1 and drives the inward transport of Cl- to neurons leading to high
levels of intracellular Cl- (Mahadevan & Woodin, 2016). This allows for outward flow of Cldown its electrochemical gradient during GABAR binding, therefore having a depolarizing
effect on neurons. While typically not associated with disease, recent evidence has
pointed toward mutations and deletions in the NKCC1 encoding SLC12A2 gene
associated with several disease phenotypes (Koumangoye, Bastarache, & Delpire,
2020).
In contrast to immature neurons, mature neurons maintain high low levels of
intracellular Cl- which correlates with higher levels of K-Cl cotransporter isoform 2 (KCC2)
(Payne, 1997). KCC2 is a neuron specific transmembrane cotransporter under the solutecarrier 12 (SLC12) family and is encoded by the SLC12A5 gene (R. Liu, Wang, Liang,
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Zhang, & Yang, 2020). GABAA-mediated hyperpolarization is dependent on KCC2
function to allow for rapid Cl- influx and synaptic inhibition. KCC2 is upregulated during
development by brain-derived neurotrophic factor (BDNF) signaling via the tropomyosin
receptor kinase-B (TrkB) leading to displacement of NKCC1 (Lee-Hotta, Uchiyama, &
Kametaka, 2019). The developmental switch from NKCC1 to KCC2 ionic regulation is
vital to postnatal survival as KCC2-deficient mice die immediately after birth due to severe
motor defects and lack of respiration (CA Hübner, V Stein, I Hermans-Borgmeyer, T
Meyer, K Ballanyi, 2001).
While hyperexcitability and neurotoxicity from excessive glutamate and NMDAR
activation have long been at the forefront of many neuroinflammatory diseases,
decreased expression of KCC2 is reported in several neurological disorders, the most
prominent being epilepsy (Chen et al., 2017; Pisella et al., 2019; Rivera et al., 2002).
Chen et al. showed that severity of epileptiform activity in cyclothiazide (CTZ)-induced
seizure mice was correlated with changes to membrane levels of KCC2. The membrane
stability and activity of KCC2 is highly regulated via phosphorylation of several tyrosine
and serine residues along the C-terminal of membrane-bound KCC2 (Lee HH, R Jurd,
2010; Pisella et al., 2019; Silayeva L, TZ Deeb, RM Hines, MR Kelley, MB Munoz, HH
Lee, NJ Brandon, J Dunlop, J Maguire, PA Davies, 2015). Of importance, Lee et al. (2015)
showed that glutamate induces dephosphorylation of S940 via a Ca2+-dependent
mechanism through NMDARs and pS940 levels are correlated with membrane levels of
KCC2. While loss of pS940-KCC2 does not affect its basal activity, there is a chloride
extrusion deficit following glutamate exposure (Silayeva L, TZ Deeb, RM Hines, MR
Kelley, MB Munoz, HH Lee, NJ Brandon, J Dunlop, J Maguire, PA Davies, 2015). These
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studies show the importance of KCC2 regulation in neuroinflammatory diseases,
especially during scenarios involving excitotoxicity.
As the importance of post-translational modification and membrane stability of
KCC2 in CNS disorders became more documented, Gagnon et al. (Gagnon, M, MJ
Bergeron, G Lavertu, A Castonguay, S Tripathy, RP Bonin, J Perez-Sanchez, D
Boudreau, B Wang, L Dumas, I Valade, K Bachand, M Jacob-Wagner, C Tardif, I
Kianicka, P Isenring, G Attardo, JA Coull, 2013) developed the compound CLP257 to
combat loss of KCC2 activity. This group used a high throughput drug screen to determine
the best compounds the enhance Cl- extrusion in cells expressing low levels of KCC2,
mimicking pathological conditions. Through this they discovered CLP257 which was able
to restore Cl- efflux in mature spinal cord neurons as well as increase cell surface
expression of KCC2. To increase efficacy and pharmacokinetics of CLP257, Gagnon et
al. (2017) designed the CLP257 prodrug CLP290 which improved the overall
pharmacokinetic profile compared to CLP257.
TMEM16a:
While KCC2 is the main transporter for maintaining Cl- equilibrium potential, ionic
regulation a highly regulated process performed by many transmembrane proteins and
intracellular signals. Following NMDAR- and Ca2+-mediated KCC2 downregulation, it is
possible other channels or transporters compensate for the lack of KCC2 Cl- extrusion.
Following Tat ± morphine exposure, neurons overload with Ca2+ via both NMDAR
activation and release from internal stores. Ca2+ is a strong downstream signaling
molecule that regulates many cellular processes. To investigate other possible KCC2-
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related mechanisms, we sought to investigate other Cl- regulating channels involving
Ca2+.
TMEM16a or Anoctamin-1 (ANO1) is a Ca2+-activated Cl- channel (CaCC) involved
in cellular processes such as cell survival, proliferation, and neuronal excitation (Dulin,
2020). CaCCs have primarily been identified in small and large sensory neurons that are
sensitive to elevated intracellular Ca2+ concentration ([Ca2+]i) in both the CNS and
peripheral nervous system (PNS) (Ji et al., 2019), although recent evidence has shown
TMEM16a is expressed in cholinergic neurons of the medial habenula via in situ
hybridization (Cho et al., 2020). TMEM16a is classically studied in the context of cancer
and lung function. TMEM16a is overexpressed in many tumors which can lead to
overactivation of several cancer cell survival and signaling pathways such as extracellular
signal-regulating kinase (Erk1/2), nuclear factor kappa-light-chain-enhancer of activated
B-cells (NFκB), and epidermal growth factor receptor (EGFR) (H. Wang et al., 2017).
Additionally, TMEM16a has recently been reported to improve airway function in cystic
fibrosis as an alternative mechanism for Cl- excretion. A tissue specific knockout of
TMEM16a in ciliated airway epithelial cells (by crossing of TMEM16Aflox/flox mice with
FoxJ1-Cre mice) leads to mucus accumulation during inflammatory lung disease by
disrupting Cl- conductance and subsequent fluid and mucus secretion (Benedetto,
Cabrita, Schreiber, & Kunzelmann, 2019; Benedetto et al., 2017). While there have been
no reports of TMEM16a being directly involved in HIV neuropathogenesis, alterations in
TMEM16a are known to contribute to HIV-induced diarrhea, which is most likely results
from excess Cl− and water retention in the colon (Chaudhury, 2015). Crofelemer, an FDA
approved, antiretroviral drug blocks TMEM16a mediated Cl- and fluid secretion which
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would lead to HIV-induced diarrhea (Crutchley, Miller, & Garey, 2010). These findings
suggest overactivation or expression of TMEM16a at least in secretory cells of the
intestines during HIV and potentially other regions highly affected by HIV such as the
brain.
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Chapter 2: In vivo morphine administration leads to anxietylike behavior and decreased exploration
Abstract
While cART has improved the lifespan and quality of life of PLWH, there is still
approximately 50% of patients who present with HAND which is reflective of the pre-cART
era. This is likely due, in part, to the expression, harboring, and transfer of the HIV-1 viral
protein Tat even in people on cART. Tat triggers the release of proinflammatory cytokines
and a neurotoxic environment leading to sublethal neuronal damage and GABAergic
dysfunction, which can be exacerbated with opioid use. In these studies, we used the
GFAP-driven DOX-inducible Tat-transgenic mouse model in combination with 2-weeks of
escalating morphine administration ± the KCC2 enhancing prodrug CLP290 to
understand the role of KCC2 function in Tat- and morphine-induced neurodegeneration
in female mice. Here, we demonstrate that 1 hour after the final morphine administration,
morphine by itself increased anxiety-like behavior and decreased exploration regardless
of genotype or CLP290 administration, while Tat had minimal effect on these outcomes.
Enhancement of KCC2 with CLP290 has no effect on morphine-induced behavioral
changes. These data provide evidence that 1 hour after morphine administration
morphine is anxiogenic, as well as a sex-dependent divergence in behavioral responses
to Tat expression when compared to previous studies.

Introduction
Behavioral tests are a strong method to examine overarching phenotypes of CNS
and other disease models that allow for more targeted investigations at the molecular
level. To understand in vivo contributions of intrinsically neurotoxic HIV-1 proteins,
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transgenic models for both Tat and gp120 have been generated. We use a Tat-transgenic
model as Tat levels still persist in the CNS and continue to be transcribed in infected
macrophages even in patients with successful cART treatment, making it a good model
to study many features of HAND (Carvallo et al., 2017). The doxycycline (DOX)-inducible
driven tet-on HIV-1IIIB Tat1-86 transgenic mouse model has been extensively used to study
the effects of HIV-1 Tat expression alone and in combination with opioids (Barbour, Nass,
Hahn, Hauser, & Knapp, 2021; Bruce-Keller et al., 2008; Fitting et al., 2012; Hauser et
al., 2009). In vivo exposure to Tat causes increased anxiety (Yun K Hahn et al., 2016;
Schier et al., 2017b), locomotor changes (Barbour et al., 2021; Fitting et al., 2012), and
learning and memory deficits (Carey, Sypek, Singh, Kaufman, & McLaughlin, 2012; Marks
et al., 2021, 2016).
The striatum is the main output center of the basal ganglia and is involved in
functions such as reward, anxiety, locomotion, and addiction and is particularly vulnerable
to HIV. Within the striatum, the cellular composition consists primarily of GABAergic
medium spiny neurons (MSNs) which make up 95% of all neurons. MSNs can be divided
into two classes, the dopamine-1 receptor (D1R)-expressing and the dopamine-2
receptor (D2R)-expressing neurons. Exposure to HIV-1 Tat ± morphine leads to
decreased dendritic spine density, spine plasticity, GABAergic function, and importantly
loss of KCC2 on MSNs and within the striatum (Barbour, Hauser, McQuiston, & Knapp,
2020; Hauser et al., 2005; Schier et al., 2017a). Interestingly, in addition to overall lower
KCC2 protein levels within the striatum, Barbour et al. discovered selective loss of
membrane localized KCC2 on D2R-MSNs specifically. This region-specific loss of KCC2
was found in Tat-transgenic mice that displayed hyperactivity in an open field test(Barbour
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et al., 2021). Interestingly, administration of KCC2-enhancing pro-drug CLP290 rescued
the hyperactive phenotype.
To further understand the role of KCC2 function in HIV-1 Tat striatal
neurodegeneration and behavioral phenotypes, we sought to understand (i) how HIV-1
Tat exposure effects female mice, (ii) whether there is any independent or interactive
effect of morphine, and (iii) how CLP290 may influence any of these outcomes. We found
that a 2-week ramping dose of morphine lead to increased anxiety-like behavior and
decreased exploration in both mice lacking (Tat-) and expressing (Tat+) the tattransgene. Interestingly, we did not see any effects of Tat or CLP290 in any behavioral
outcomes.

Methods
Animals
All animal procedures were approved by the Institutional Animal Care and Use
Committee at Virginia Commonwealth University and were in accordance with ethical
guidelines defined by the National Institutes of Health. For all studies, 4–6-month-old
female doxycycline (DOX)-inducible HIV-1 Tat transgenic mice were used. Mice
expressing the rtTA ± the tat transgene were fed a standard chow supplemented with
DOX (6 mg/g, Harlan Indianapolis, IN) for two weeks prior to experimentation. Mice were
housed 4-5 per cage with ad libitum access to food and water in a temperature- and
humidity-controlled facility on a 12:12h light-dark cycle.
Drug administration
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A subset of mice was administered a ramping dose (10, 20, 30, and 40 mg/kg) of
morphine sulfate (s.c.) twice per day (b.i.d.) with the dose increasing 10 mg/kg at 2-day
intervals until a 40 mg/kg, b.i.d., dose is reached on day 7. A 40 mg/kg morphine b.i.d.
dose is given thereafter (days 7-14). As a control, another group of mice received saline
injections (s.c.) twice per day in equivalent volumes. Additionally, select mice received 30
mg/kg (200 µl/mouse) of KCC2 enhancing pro-drug CLP290 via oral gavage once per
day prior to morphine or saline injection. Control mice for CLP290 were administered the
drug vehicle solution (20% hydroxypropyl-beta-cyclodextrin (HPCD) in dimethyl sulfoxide
(DMSO)) via oral gavage (200 µl /mouse).

Behavioral Assays
Prior to behavioral assays, all mice were acclimated to the testing room overnight prior to
testing day. On the test day, treatment timing was staggered so each mouse was tested
at the same time interval following treatment.
Open Field: Spontaneous locomotor activity was assessed using an open field
chamber 1 hour-post morphine (or saline) injections at 9 am. Mice were placed in the
center of a square Plexiglas box (40 × 40 × 35 cm; ANY-maze, Stoelting Co., Wood Dale,
IL) and allowed to explore freely for 20 minutes. ANY-maze software was used for threepoint video tracking of all mice while in the open-field. The area within the open field was
arbitrarily divided into a 3 × 3 grid consisting of 9 ‘zones’. Computer-aided video tracking
using ANY-maze software was used to determine the number of zone entries and time
spent within each zone during each 20-minute trial. Average speed, distance traveled,
time spent mobile, time in center zone, number of center zone crossings, and number of
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rears were tracked and used as indices of motor and exploratory, and anxiety-like
behaviors.
Rotarod: Evoked locomotion was assessed using a single trial of a rotarod test.
Mice were placed on a 3 cm diameter immobile rod suspended at a height of 44.5 cm
(Columbus Instruments) facing the back of the rotarod chamber (Rotamex-5, Columbus
Instruments, Columbus, OH). The rotarod apparatus consists of a rotating spindle (3 cm
diameter) separated by dividers into four sectors (9.5 cm wide) allowing for the
simultaneous testing of four mice. Mice were tested on a single accelerating speed trial
(starting at 0 rpm, acceleration step of 1 rpm, 7.5 s intervals) with no performance ceiling.
Evoked locomotor behavior was recorded using Rotamex-5 software and assessed by
measuring latency to fall.

Statistics
For all experiments, a 3-way analysis of variance (ANOVA) was used to examine
main effects and interactions between Tat ± morphine and ± CLP290 treatment groups.
To look at multiple comparisons, a post-hoc analysis was performed using a Fishers-LSD
test. Data are shown as the mean ± the standard error of mean (SEM) and the findings
are considered significant if p < 0.05. All data was analyzed using Prism 9 (GraphPad)
statistical software.

Results
Morphine-treated mice show an increase in anxiety like behavior
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Exposure to a ramping dose of morphine increased behavior that is indicative of
anxiety in mice and reduced exploratory behavior in an open field test. Both Tat(−) and
Tat(+) (n = 8) morphine-treated mice had fewer center entries, time spent in center of the
box, and less rears compared to saline treated mice over the 20-minute test (p < 0.001)
(Fig. 1). These effects are not due to motor impairment or lethargy as mice in all groups
did not differ in their distance traveled or performance on a rotarod test. Mice also did not
differ in mean speed or time spent mobile during the open-field test (Table 1).

Discussion
The studies described in this chapter outline the effects of 2-week Tat ± morphine
exposure and how enhancement of KCC2 function via CLP290 administration influenced
behavioral outcomes in female mice. We show that a 2-week ramping dose of morphine
leads to anxiety-like behavior through decreased center entries, time spent in center, and
decreased exploratory behavior through decreased rearing. These data suggest that
morphine is disrupting specific CNS circuitry but not locomotor activity as all mice
performed similarly in an evoked locomotor task and time mobile, distance traveled, and
speed in the open-field test.
Depending on the duration, method of exposure, and dosage, HIV-1 Tat can have
differential effects. For example, the DOX-inducible Tat-transgenic model used in these
studies displays a milder pathology compared to other Tat expression models (B. O. Kim
et al., 2003; W Zou, BO Kim, BY Zhou, Y Liu, A Messing, 2007). We chose our model on
the basis that this system has a more prolonged onset that is more representative of that
seen in HIV patients. As we are looking at how Tat ± morphine mediated effects on KCC2,
we wanted to study a timeframe in which electrophysiological, synaptodendritic
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manifestations, and mild behavioral abnormalities appear prior to overt cell death and
extreme behavioral effects. Previous work at the same 2-week exposure duration
demonstrated that Tat-TG mice display decreased dendritic spine complexity and density,
increased dendritic damage, anxiety-like behavior, and hyperlocomotion along with loss
of KCC2 (Barbour et al., 2020, 2021; Schier et al., 2017b). While we saw an anxiety-like
behavior phenotype, it was solely due to morphine administration with no interactions with
Tat-expression or KCC2 modulation. Further testing of other anxiety-like behavior using
a light-dark box, Although duration of Tat exposure in the present experiment was
identical to our previous studies, one difference was the use of female mice. In most
models of HIV-1 Tat exposure in vivo, experiments are conducted using only male mice.
Interestingly, Hahn et al. showed that there are sex differences in the phenotypes
observed using the same HIV-1 Tat-transgenic mouse model following 3-months of Tat
induction as these studies presented with males being more vulnerable than females (Yun
Kyung Hahn et al., 2015). Compared to the studies performed by Hahn et al. our paradigm
had the added stressor of daily s.c. injections. Morphological and physiological
differences in microglia between sexes could be another way in which Tat exposure could
lead to divergent responses. Under basal conditions, male microglia show higher
expression of the antigen presenting molecules major histocompatibility complex II,
motility regulator P2Y12, as well as larger K+ current responses to ATP-stimulation,
suggestive of heighten reactivity compared to female microglia (Guneykaya et al., 2018;
Yanguas-Casás, 2020). Additionally, in a comparative study using a NFκB-luc2 mouse
model to investigate inflammatory status of cells in vivo, RNA sequencing analysis of
isolated microglia showed 79% of 95 inflammatory genes were upregulated in males
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compared to females (Villa et al., 2018). These studies could explain a lack of a Tat
response due to weakened immune and inflammatory response to Tat expression
compared to male mice. Further, side-by-side investigations into male versus female
responses to Tat at the behavioral level as well as molecular studies looking into sex
differences in glial inflammatory responses are needed. Lastly, careful examination of
the video recordings in morphine-treated mice revealed considerable fine stereotypic
motor movements (e.g., pivoting back-and-forth on hindpaws that are stationary) that the
ANY-maze software often interpreted as inactivity. Future studies should consider
examining additional fine motor behaviors, such as wet-dog shakes or paw flutters, which
can accompany opioid withdrawal, when assessing the interactive effects of opioids and
HIV in mice.
In addition to our use of female mice, our studies differed from similar studies by
Barbour et al. these mice received s.c. injections twice a day for the duration of the study.
Studies have shown that repeated injections lead to a generalized vital stress response
in mice with an increase in heart rate and body temperature lasting around 30 minutes
(Meijer, Spruijt, Van Zutphen, & Baumans, 2006) and Paris et al. have found increases in
corticosteroids in male mice injected with morphine or saline regardless of whether they
express Tat (Paris et al., 2020 Neurobiology of Stress). This body response is likely
related to increased levels of serum proinflammatory cytokines and increased
corticosterone following saline injection (Du Preez et al., 2020). Although our behavioral
tests were done 1 hour following saline or morphine injection, it is still possible a stress
response from the injection could have induced behavioral changes in the open field test
when combined with HIV-1 Tat exposure that differ from non-injected Tat-transgenic
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mice. Addtionally, males and females can have differing responses to stress and related
disorders. For example, corticotropin-releasing factor (CRF) levels are higher in females
compared to males such as the paraventricular nucleus and amygdala (Iwasaki-Sekino,
Mano-Otagiri, Ohata, Yamauchi, & Shibasaki, 2009). Excessive release of CRF is
implicated in depression, stress, and anxiety disorders which are more common in
females compared to males (Wiersielis et al., 2016). This suggests that females could be
more sensitive to the stressors in our studies and another reason why the anxiety-like
behaviors of less center entries and time spent in center may not be seen in previous
studies with males (Barbour et al., 2021). In future studies, evaluation of the estrous cycle
in female mice should be considered as proestrus females have higher neuronal
activation within the infralimbic region as well as a positive correlation with grooming
behavior that are not seen in diestrus females or males (Wiersielis et al., 2016). While we
performed behavioral tests and treatment at the same time every day, differences in
estrous cycle between mice could be masking or biasing results seen.
We wanted to test the direct response to morphine administration on behavioral
outcomes, but most studies involving anxiety and opioids involves looking at the
withdrawal response. While the withdrawal response to opioids, such as morphine, results
in anxiolytic behavior, the direct response following administration has been shown to be
anxiogenic in rodents (Chaoliang, Gu, Li Peng, Hu Bi, Ouyang Xinping, Fu Juan, Gao
Jun, Song Zeng, Han Li, Ma Yuanye, Tian Shaowen, 2008; Kudryavtseva, Gerrits,
Avgustinovich, Tenditnik, & Van Ree, 2004). Compared to the κ- (kappa) and δ-(delta)
opioid receptors, morphine has the strongest affinity for the mu opioid receptor. While any
morphine effects is most likely through the µ-receptor, both the µ-opioid and k-opioid
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receptor-specific agonists can produce anxiogenic behaviors in rodents (Kudryavtseva et
al., 2004; Y. J. Wang et al., 2016). The results of opioid receptor activation are dependent
on the route of administration, dosage, and timing. For example, Intraperitoneal (i.p.)
administration of the kappa-opioid receptor agonist U50,488H produces an anxiolytic
effect at low doses but an anxiogenic effect at higher doses which correlate with
respective changes to ERK1/2 phosphorylation (Y. J. Wang et al., 2016). Additionally, we
pursued the acute response to morphine due to its interactions with KCC2 regulation.
Downregulation of KCC2 is a key component to the development of morphine-induced
hyperalgesia (Tang, D, AH Qian, DD Song & WY, Yao, J Sun, WG Li, TL Xu, 2015).
Weakening of GABAergic inhibition of spinal dorsal horn neurons from KCC2
downregulation as well as morphine-induced hyperalgesia are restored with concurrent
CLP290 administration (F Ferrini, T Trang, TA Mattioli, S Laffray, T Del’Guidice, LE
Lorenzo, A Castonguay, N Doyon, W Zhang, AG Godin, D Mohr, S Beggs, K Vandal, JM
Beaulieu, CM Cahill, MW Salter, 2013; Ferrini, Lorenzo, Godin, Quang, & De Koninck,
2017). We performed our open field test 60 minutes following morphine injections and we
could have potentially missed the window for morphine-induced locomotion. Several
studies have seen that immediately post-morphine administration and then approximately
2-hours post-administration there are increases in locomotion (Murphy, Lam, &
Maidment, 2001; Vanderschuren, Schoffelmeer, Mulder, & De Vries, 1999). Additionally,
the half-life of morphine in plasma is under 60 minutes in mice therefore reduced levels
of morphine at our experimental timepoint could result in lack of locomotion (Zelcer et al.,
2005). Our results highlight and partially recapitulate the effect of morphine on anxiogenic
behavior. To understand the role of sex differences in Tat-induced behavioral
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phenotypes, direct side-by-side comparisons of males and females need to be explored
in further studies.
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Fig 1. Morphine-treated mice showed anxiety-like behavior and decreased
exploratory behavior. Morphine-treated mice showed anxiety-like behavior with less
center entries compared to the saline group (A) as well as fewer entries into the center
zone of the open-field (B) (***, p < 0.001, n=8). Additionally, morphine-treated mice
showed less exploratory behavior measured by number of rears during the trial (C) (***,
p < 0.001, n = 8).
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Table 1. Effects of morphine and Tat and CLP290 on open-field behavior.
Behavioral
Measure

Main
Effect

Saline
Mean ± SEM
(CLP290)

Morphine
Mean ± SEM
(CLP290)

Significance
(p-value)

Center

Morphine

29.875 ± 7.645

3.714 ± 3.386

*** ; p < 0.0001

(37.429 ± 0.055)

(3.125 ± 4.250)

69.625 ± 17.945

13.114 ± 12.915

(73.286 ± 25.112)

(5.013 ± 2.304)

82.500 ± 13.399

8.000 ± 6.849

(92.286 ± 17.992)

(16.625 ± 10.502)

29.542 ± 3.258

24.310 ± 9.791

(30.594 ± 3.822)

(43.236 ± 16.552)

591.038 ± 53.232

546.686 ± 82.155

(597.129 ± 59.231)

(626.875 ± 113.136)

0.025 ± 0.003

0.020 ± 0.008

(0.026 ± 0.004)

(0.036 ± 0.014)

62.925 ± 9.485

68.114 ± 11.474

(67.286 ± 11.744)

(79.863 ± 7.890)

Entries
Time in

Morphine

Center
Number of

Morphine

Rears
Distance

None

Traveled
Time

None

Mobile
Mean

None

Speed
Rotarod

None

*** ; p < 0.0001

*** ; p < 0.0001

ns

ns

ns

ns

Statistical outcome for all behavioral measures recorded. Main effects of the 3-way
ANOVA are shown alongside mean values for each behavioral outcome ± the standard
error of the mean (SEM) for saline and morphine treated mice in both the vehicle and
CLP290 groups.
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Chapter 3: CLP290 administration increases expression
levels of KCC2 but decreases Cl- channel TMEM16a in the
striatum
Abstract
The striatum is highly affected by HIV and susceptible to neuronal damage by viral
proteins such as Tat. HIV-1 proteins, inflammatory mediators, and excitotoxic molecules
released and recruited by infected cells lead to sublethal neuronal damage, providing the
neural basis of HAND. While it has been demonstrated that the HIV viral protein, Tat, is
synergistically excitotoxic with morphine through mechanisms involving NMDA and αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activation (Fitting
et la., 2014), little is known about how HIV-1 Tat interacts with opioids on GABAergic
systems. Recent work has shown that following exposure to HIV-1 Tat downregulates
KCC2 in vitro and in vivo, reduced KCC2 phosphorylation at S940 in vivo, and disrupts
GABAAR mediated hyperpolarization in vitro (Barbour et al., 2020, 2021). We used DOXinducible, GFAP driven Tat-transgenic mice and used western blotting analysis to assess
protein level changes in the striatum. We found that CLP290 increased levels of KCC2
but did not increase phosphorylation at S940, but no treatment had any effects on
NKCC1. Lastly, we found that Tat and CLP290 decreased levels of the chloride channel
TMEM16a. These results show that in female mice, Tat and morphine have minimal
effects on KCC2 protein levels and phosphorylation. Additionally, our data suggests
TMEM16a is another way in which Tat can dysregulate GABAergic function which could
be linked to KCC2 as CLP290 decreased TMEM16a immunoreactivity.
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Introduction
Recent evidence in post-mortem tissue samples from HIV-infected individuals and
in Tat transgenic mice in vivo suggests GABAergic neurons are selectively vulnerable to
(Buzhdygan et al., 2016; Marks et al., 2016; Xu & Fitting, 2016). The cellular composition
of the striatum is unique compared to other brain regions as a vast majority of the
principal, projection neuronal populations, and some interneuronal subpopulations, are
GABAergic. Within the striatum, about 90-95% of neurons in adult rodents are GABAergic
MSNs and 4-5% being various types of GABAergic interneurons (Gagnon et al., 2017;
Gerfen & Surmeier, 2011). GABAergic neurons rely on a strong inward driving force for
Cl- through maintenance of low levels of intracellular Cl-. This ionic gradient allows for the
rapid hyperpolarization and proper inhibition of neurons upon GABAA receptor (GABAAR)
binding. In mature neurons the Cl- gradient is primarily controlled by KCC2. KCC2 is highly
regulated at both the transcriptional and post-translational level (Kahle et al., 2013; LeeHotta et al., 2019). Previous work has shown that KCC2 is downregulated in the striatum
of Tat-transgenic mice (Barbour et al., 2020). While administration of CLP290 does not
increase total KCC2 levels, CLP290 reverses Tat-dependent decreases in KCC2
phosphorylation at S940—resulting in increased KCC2 phosphorylation, trafficking to the
cell membrane, and activation. Moreover, The Tat-dependent reductions in KCC2 p-S940
and localization at the cell membrane KCC2 was only evident in D2R (but not D1R)
medium spiny neurons (MSNs) (Barbour et al., 2021), although deficits in KCC2 may
occur in D1R MSNs with more prolonged (> 1 month) Tat exposure since D1 MSNs
display a more delayed onset, less severe pathology than D2R MSNs following 2 months
of Tat induction (Lark et al., submitted for publication). Our work plays off these studies
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and looks to advance this line of research by investigating morphine by itself and in
combination with Tat .
Ionic homeostasis is controlled by a series of checks and balances through the
actions of transmembrane channels and transporters. While channels allow for the flow
of ions based on the driving force determined by their respective electrochemical
gradients, transporters use ATP-driven energy to move ions against their electrochemical
gradients (Dubyak, 2004). In Tat-transgenic mice, striatal neurons are overloaded with
Ca2+, which results in dendritic spine swelling and varicosities. While KCC2 is
downregulated via a Ca2+-dependent mechanism, it is logical that other channels or
transporters attempt to compensate for deficits in Cl- extrusion accompanied by shortfalls
in KCC2 function. The CaCC, TMEM16a is activated by an increase in intracellular Ca2+
concentration ([Ca2+]i) resulting in increased Cl- conductance. TMEM16a dysfunction is
implicated in some neoplasias including gastrointestinal, squamous cell carcinomas,
breast, pancreatic, and prostate cancers (Le, Correspondence, Yang, & Yang, 2020).
While there is not yet a link to HIV-mediated neurodegeneration, blockage of TMEM16a
by ART drugs leads to HIV-induced diarrhea (Crutchley et al., 2010). TMEM16a is
functionally active in cholinergic neurons of the medial habenula and plays an important
role in regulating anxiety-like behavior (Cho et al., 2020). Additionally, there is evidence
that the related CaCC, TMEM16b is active in GABAergic neurons of the amygdala and
that deleting the TMEM16b encoding gene ano2 leads to impaired context-independent
fear memory (Li Ke-Xin, He Mu, Ye Wenlei, Simms Jeffrey, Gill Michael, Xiang Xuaner,
Jan Yuh Nung, 2019). This finding led to us investigate whether the expression of
TMEM16a was affected by Tat ± morphine-dependent deficits in KCC2 and the extent to
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which KCC2 enhancement with CLP290 might reverse putative alterations in TMEM16a.
Although we found there was no influence of Tat and or morphine on KCC2 or pS940KCC2 levels, Tat expression did lower levels of TMEM16a. Although CLP290 did not
rescue KCC2 and TMEM16a levels of both KCC2 and TMEM16a tended to increase in
mice administered CLP290.

Methods
Western Blotting
Whole striata (single hemisphere) from 4-6 month old female mice used in the
behavioral assessments were harvested at 1pm each testing day. Striata were
homogenized in RIPA buffer (Sigma) containing 100× HALTTM Protease and
Phosphatase inhibitor cocktail (Thermo Fisher) to prevent protein degradation. Protein
lysate supernatants were aliquoted and stored at -80º C until use. Protein concentration
was measured using a BCA protein assay (Pierce, Rockford, IL). Samples of 40 µl lysates
were loaded into 4-20% gradient Criterion Pre-Cast Gels (Bio-Rad Laboratories,
Hercules, CA) and ran at 100V. Gels were transferred onto PVDF membranes (Bio-Rad)
and probed with anti-KCC2 (1:2000; Protein Tech, Rosemont, IL), anti-pS940 KCC2
(1:1000, Abcam), anti-NKCC1 (1:1000; Protein Tech, Rosemont, IL), anti-TMEM16a
(1:500; Bioss), and anti-GAPDH (1:2000, Abcam) primary antibodies. KCC2 and GAPDH
were detected by measuring fluorescent signal from Alexa Fluor 488 and 647-conjugated
secondary antibodies (1:1000). TMEM16a, NKCC1, and pS940-KCC2 were detected
using a horseradish peroxidase (HRP) anti-rabbit secondary antibody and Super Signal
West Femto Maximum Sensitivity Substrate Kit (Thermo Fisher).
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Results
CLP290 administration increased striatal KCC2 levels but had no effect on pS940KCC2 levels
We have seen reduced striatal KCC2 expression in Tat transgenic male mice
following 2 weeks of DOX-administration. To see if these findings translate to female
mice, we performed western blot analysis of harvested striatal tissue. In female mice,
overall mice administered showed higher levels of KCC2 regardless of genotype or
morphine treatment (Fig. 2A). While KCC2 levels in Tat+ mice were not significantly
different from control, Tat+ mice ± morphine displayed significantly higher KCC2 levels
compared to non-CLP treated mice (Fig. 2A, D, E).
As CLP290 enhanced KCC2 activation via phosphorylation, we investigated levels
of pS940-KCC2. Interestingly, while CLP increased overall KCC2 levels, CLP had no
effect on pS940-KCC2 levels (Fig. 2B, D, E) and there were no effects of either morphine
or Tat exposure. These data potentially suggest an alternative mechanism by which CLP
is increasing KCC2 levels such as increased protein stability or lack of degradation.
Additionally, to investigate a potential reversal of the developmental shift between NKCC1
and KCC2 expression, we probed for levels of NKCC1. We saw no significant changes in
striatal NKCC1 levels due to Tat, morphine, or CLP290 treatments (Fig 3A-C).

HIV-1 Tat and CLP290 independently decreased TMEM16a immunoreactivity
To investigate potential connected or compensatory changes to related Clregulators, we probed for TMEM16a from striatal tissue lysates. Western blot analysis
showed a main effect of CLP290 decreasing TMEM16a immunoreactivity (Fig. 3; p <
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0.05) with no interaction with genotype or morphine treatment. Post-hoc analysis revealed
Tat expressing mice have decreased TMEM16a levels compared to saline-vehicle
controls regardless of CLP290 administration (Fisher’s LSD, p < 0.05). These data
suggest that Tat exposure either directly or indirectly decreases TMEM16a levels but this
appears to be unrelated to KCC2 stability.

Discussion
The studies in this chapter describe the effects of Tat expression and morphine
administration on Cl- transporter and channel levels in striatal tissue lysates and the role
of KCC2 via enhancement with CLP290. We show that CLP290 increases striatal KCC2
immunoreactivity but does not influence pS940 levels. Also, there were no changes to the
ratio of pS940-KCC2:KCC2 or NKCC1 levels. These data suggest that TMEM16a is an
alternative target for HIV-1 Tat to disrupt Cl- regulation and GABAergic function.
Additionally, these data show a potential sex-difference in KCC2 regulation by Tat and
CLP290 as our results differ from previous literature which uses male mice (Barbour et
al., 2020, 2021). Tat induction has been shown to decrease striatal KCC2 levels through
a decrease in phosphorylation at S940, with CLP290 administration rescuing pS940KCC2 levels and KCC2 membrane stability (Barbour et al., 2020). While CLP290 did in
fact increase KCC2 levels, we did not see a rescue as there was no Tat induced KCC2
loss nor did CLP290 increase pS940 levels. This suggests that in our cohort of female
mice, CLP290 increased basal KCC2 protein expression through a mechanism other than
stabilizing S940 phosphorylation. KCC2 is highly regulated at the post-transcriptional
level and its membrane stability is regulated by phosphorylation at S940 via protein-
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kinase C (PKC) (Lee et al., 2007). Conversely, dephosphorylation of KCC2 at S940 is
mediated through protein phosphorylase 1 (PP1) through and NMDA dependent
mechanism (Lee, Deeb, Walker, Davies, & Moss, 2011). There is no conclusive evidence
to whether CLP290 acts directly at KCC2, the PKC, or PP1 levels. Our data shows that
there is no increase in phosphorylation but KCC2 levels are increased with CLP290
administration. This suggests that in our studies, CLP290 is not enhancing
phosphorylation of KCC2 but potentially blocking dephosphorylation through PP1 to
increase stability. Whether PP1 activity or expression is influenced by CLP290 needs to
be explored in further studies. Additionally, a cohort of both male and female mice should
be used in future studies to explore sex differences in Tat and morphine induced KCC2
dysregulation as well as differential CLP290 effects.
Our studies are the first investigating TMEM16a in the brain in regard to HIV-1 Tat
expression. While the cell type expression of TMEM16a in the brain is not fully
understood, the Brain Seq database (https://www.brainrnaseq.org) from the Barres
Laboratory shows that TMEM16a encoding gene ano1 is detected at low levels in
neurons, oligodendrocytes, and microglia with highest expression in astrocytes (Zhang et
al., 2014). More specifically in the lateral habenula, the loss of TMEM16a expression in
cholinergic neurons has been implicated in mediating anxiety-like behaviors in mice (Cho
et al., 2020). To further understand TMEM16a function in the striatum, fluorescent in situ
hybridization and immunohistochemistry studies should be performed to investigate
TMEM16a expression at the gene and protein level in specific cell types. Performing
these studies in Tat-transgenic mice would confirm our immunoblotting results, as well as
determine if loss of TMEM16a immunoreactivity is specific to a particular cell type.
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Fig 2. CLP increases striatal KCC2 immunoreactivity but has no effect on S940
phosphorylation. Representative western blot bands from striatal protein lysates from
all treatment groups either administered drug vehicle (D) or CLP290 (E). Mice
administered CLP290 show increased levels of KCC2 immunoreactivity (A) with no
difference in levels of pS490-KCC2 (B), the ratio of pS940: unphosphorylated KCC2 (C),
(*p < 0.05; ***p < 0.001; n = 6).
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individual animal. Bands from striatal protein lysates from all treatment groups either
administered drug vehicle (A) or CLP290 (B).
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immunoreactivity (B,C) compared to drug vehicle (* p < 0.05). Post-hoc analysis shows a
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Chapter 4: Investigating other mechanisms of Cldysregulation and inflammation
Abstract
The striatum is a central interface for addiction circuits that becomes dysregulated
by opiates and harbors high viral loads making it susceptible to neuropathology in HIV
infected individuals. While neurons do not become infected with HIV, glial cells, such as
microglia and astrocytes, are preferentially targeted and are the source of many sublethal
neuronal effects associated with HAND. Exposure to HIV or viral proteins leads to release
of proinflammatory cytokines and chemokines from glial cells which is exacerbated by
opioids such as morphine. We used the LEGENDplexÔ bead-based immunoassay on
the striatum of DOX-inducible, GFAP-driven Tat-transgenic mice to analyze cytokine and
chemokine levels. We found that morphine alters levels of proinflammatory cytokines IL23 and IFN-b and that CLP290 treated Tat+ mice show significantly higher levels of IFNb compared to Tat+ mice administered drug vehicle. When total mean cytokine
concentrations were averaged, we found that cytokine levels increase with age in Tatmice with increasing age, while they decreased from 4-6 months in Tat+ mice.
Additionally, chemokine levels were relatively unchanged, but morphine did alter
concentrations of Eotaxin (CCL11) depending on Tat-transgene expression. Contrary to
cytokines, we found that total mean chemokine levels decreased with age in both Tatand Tat+ mice. Lastly, we mined existing Next-Gen RNA seq data and found no
detectable gene expression changes following acute Tat and morphine exposure in genes
encoding Cl- channels, transporters, or GABA receptors.
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Introduction
Even with effective cART, PLWH still display high levels on inflammation compared
to non-infected individuals (Neuhaus et al., 2010). Sustained inflammation without
ongoing viral replication is likely due to cellular reservoirs of HIV-1 in the brain. Microglia
are the primary reservoir harboring latent HIV-1 and while a low percentage of astrocytes
integrate HIV-1 DNA, they are capable of transferring virus and viral protein to other cells
(Valdebenito, Castellano, Ajasin, & Eugenin, 2021; Wallet et al., 2019). HIV-1 and its viral
proteins lead to activation of both microglia and astrocytes which results in expression
and release of proinflammatory cytokines and chemokines. PLWH show an increased
level of proinflammatory markers such as IFN-g, TNFa, IL-6, IL-1a, IL-2, and IL-12, some
of which can still be elevated following well beyond the initiation of cART treatment
(Abassi et al., 2017; Nolting et al., 2012; Osuji, Onyenekwe, Ahaneku, & Ukibe, 2018).
Prescription and illicit use of opioids are highly comorbid with HIV-1 infection.
Drugs of abuse, including opioids, have been shown to worsen HIV neuropathology (Bell,
Brettle, Chiswick, & Simmonds, 1998; Steele, Henderson, & Rogers, 2003) and
neurological outcomes (Byrd et al., 2011; Cernasev et al., 2020) in HAND in both the precART and cART eras.

Methods
LEGENDplex Flow Cytometry Cytokine and Chemokine Panels
All reagents used were from LEGENDplex™ Mouse Inflammation Panel
(BioLegend, San Diego, CA) and LEGENDplex™ Mouse Proinflammatory Chemokine
Panel (BioLegend, San Diego, CA) kits. Using the same harvested tissue from the 4-6
month female mice for western blot analysis, the opposite hemisphere for each mouse
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was homogenized in LEGENDplex Assay Buffer. Protein lysate supernatants were
aliquoted and stored at −80 ºC until use. Reconstituted standard cocktail were prepared
in a 1:4 serial dilution starting at 10,000 pg/mL. Diluted standards and samples were
added to specified wells of a 96-well plate along with mixed beads and assay buffer. Filled
plate was mixed at room temperature (RT) for 2 hours at 800 rpm. Plate was centrifuged
at 350 g for 5 minutes until pellet formation, supernatant was decanted, and pellet was
washed with 1X wash buffer (this step is repeated). Pellet was mixed with detection
antibody and shaken at 800 rpm for 1 hour at RT. Streptavidin-PE was added to each
well to enhance biotin antibody signal and plate was shaken at 800 rpm for 30 additional
minutes. Plate was spun at 350 g for 5 minutes and pellets were washed as described
above. Final pellets were resuspended in 150 μL of wash buffer and plate was stored at
4 ºC until use.
Plate was read on a Cytek Aurora flow cytometer with a yellow-green (YG) laser
by the VCU Flow Cytometry Core. Beads were gated automatically by LEGENDplex
software and manually checked and or readjusted as needed.

Next Gen RNAseq datamining
Existing RNAseq data from male mice acutely exposed to Tat and morphine was
mined for differences in gene expression. ENSEMBLE IDs for each gene were translated
into

their

respective

gene

names

using

https://www.biotools.fr/mouse/ensembl_symbol_converter and gene expression levels
were presented as fragments per kilobase exon per million mapped fragments (FPKM).
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FPKM values for n = 3 mice per treatment group were averaged and presented on a
logarithmic scale using Prism 9 software.

Statistics
For all experiments, a 3-way analysis of variance (ANOVA) was used to examine
main effects and interactions between Tat ± morphine and ± CLP290 treatment groups.
Data is shown as the mean ± SEM and these data are considered significant if p < 0.05.
Gene expression data was analyzed using Prism 9 statistical software and LEGENDplex
data was analyzed using Prism 9 and JMP software. To look at multiple comparisons,
post-hoc analyses were performed using a Fishers-LSD test.

Results
Morphine administration affects IL-23 and INF-β concentrations and total cytokine
levels alter with age depending on Tat expression in the striatum

We first validated our data by confirming proper standard curve generation, bead
gating, and analyte detection (Fig 5A-D). Animals treated with a 2-week ramping dose of
morphine showed an increased concentration of proinflammatory cytokine IL-23 (3-way
ANOVA, p < 0.05) and a decrease in IFN-β (3-way ANOVA, p < 0.05) (Fig. 6). Though
IL-23 only showed a main effect of morphine, Tat+ mice showed a trending decrease in
IL-23 levels compared to Tat− controls (p = 0.062). INF-β showed a significant increase
in Tat+ mice when treated with CLP290 compared to Tat+ vehicle treated mice that brings
IFN-β around Tat− control levels (Fig. 6B). The mean difference between saline and
morphine groups for IFN-β is minimal (0.11), there is a trending interaction with genotype
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suggesting that the morphine main effect is mainly driven by Tat genotype. While only
individual 2 of 13 analytes showed, we wanted to investigate all cytokines combined and
examine the role of aging. Over the course of a lifetime, physiological deterioration from
tissue atrophy, metabolism, reduced cell counts, and tissue proteins are a result of aging
(Park & Yeo, 2013). One of the most common phenomena seen in the aging process is
chronic low levels of inflammation (Chung et al., 2019; Loeser, 2010). When we average
individual analytes across treatment groups, generating one mean cytokine value per
animal, and split the cohort by age, we see that Tat− mice show a significant increase in
the mean concentration of cytokine markers from 4 to 5 months in age (p< 0.05), 4 to 6
months (p < 0.05), and 5 to 6 months (p < 0.05) (Fig. 7A). Although Tat+ mice start at a
higher baseline value of mean cytokine concentration (p < 0.01) compared to Tat- mice,
Tat+ mice show a decrease in mean cytokine concentration from 4 to 6 months in age (p
< 0.05). Interestingly, these effect trends hold when we split the mice into their respective
treatment groups and when cytokines are split into pro- (solid line) and anti-inflammatory
(dotted line) markers (Fig. 8). These data suggest that Tat expression can alter age
induced cytokine alterations in females and further studies into aging markers and
phenotypes could bring more clarity to our findings.

Chemokine concentrations are relatively unaffected Tat expression and morphine
Identical to the cytokine panel, we validated our data for each cytokine by
confirming standard curve generation, bead gating, and analyte detection (Fig 9A-D).
Unfortunately, only 5 of 13 chemokines were within the limits of detection, therefore our
analysis only focuses on these. Eotaxin (CCL11) was the only chemokine to show any
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significant effect with a genotype x morphine interaction (3-way ANOVA, p < 0.05) (Fig
10A). Multiple comparisons showed that Tat- morphine treated animals that were
administered CLP show an increased concentration of eotaxin compared to vehicle
administered mice (Fisher’s LSD, p < 0.05). We also investigated the extent to which
mean chemokine levels were altered during aging and found a main effect of age in which
overall chemokine concentrations increased with age in control. Tat− mouse striatum (2way ANOVA, p < 0.05). Post-hoc analysis showed that compared to the 4-month-old
mice, 6-month-old mice had a lower mean chemokine concentration (Fisher’s LSD, p <
0.05) (Fig 11A-C). Interestingly, chemokines show an opposing trend compared to the
cytokines in our studies which increased with age.

Genes encoding Cl- channels, transporters, or GABA receptors were unaffected by
morphine and/or Tat
To investigate whether Tat and morphine exposure altered the expression of
genes relevant to KCC2 and chloride regulation, RNA sequencing data was mined from
the striatum of mice acutely exposed to Tat ± morphine. We found no changes in FPKM
values between groups in any of the genes analyzed (Fig. 12). Looking at more prolonged
exposures to Tat and morphine could provide more insight into genes involved in chloride
regulation.

Discussion
The studies in this chapter investigate inflammatory changes in the striatum and
the extent that Tat ± morphine induced KCC2 deficits or KCC2 enhancement by CLP290
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might underlie Tat ± morphine dependent inflammation. We show that 2-week morphine
administration altered striatal concentrations of IL-23 and IFN-β and that while mean
cytokine concentrations increase with age in Tat- mice, Tat+ mice slightly decrease
concentrations. Additionally, we found that there is little alteration to individual
chemokines, but mean chemokine concentrations decrease with age, as opposed to the
cytokine results. Lastly, we mined existing RNA seq data from a separate cohort of male
mice acutely exposed to Tat with or without morphine to investigate gene expression
changes to genes encoding Cl- channels, transporters, and GABA receptors. We saw no
significant differences but increasing sample size and or duration of Tat and morphine
treatment may uncover more differences.
While acute inflammation is vital to rapid responses to infection and injury, chronic,
low level inflammation can lead to tissue degeneration (Franceschi & Campisi, 2014).
Immunosenescence is a hallmark of aging and is characterized by decreased T-cell
function and altered cytokine responses (Michaud et al., 2013). In particular, TNF-a and
IL-6 are linked to cognitive decline with age and are important factors in other
inflammatory diseases (Frolich, Hofman, Jolles, Breteler, & Westendorp, 2007; Holmes
et al., 2009). While we did not see significant differences in concentrations of TNF-a or
IL-6 in the striatum, it is possible we missed the window for elevated levels of these early
cytokines, but we did see morphine effects in both IL-23 and IFN-β. IFN-β is an antiviral
cytokine and Tat-dependent increases in IFN-β were not surprising.

Unlike in the

periphery, however, IFN-β can act in both a pro- and anti-inflammatory manner in the
CNS and is a well-studied therapy for people with relapsing-remitting multiple sclerosis

48

(Filipi & Jack, 2020). Interestingly, morphine can suppress both IL-23 production and IFN
signaling, and both have implications in HIV infection.
Regulatory T lymphocytes (Tregs) are critical for maintaining immune tolerance to
self and preventing autoimmunity.

IL-23 increases Treg plasticity by increasing the

recuritment/differentiation of T helper 17 (Th17) cells that have positive of negative
consequences depending on timing and context (Kannan et al., 2019). In the periphery,
IL-23 is a clinical indicator and target for inflammatory diseases such as rheumatoid
arthritis and irritable bowel disease (Cayatte et al., 2012; Zaky & El-Nahrery, 2016). In the
CNS, IL-23 may contribute to the accumulation of β-amyloid and neurodegeneration in
Alzheimer’s disease (Nitsch, Schneider, Zimmermann, & Müller, 2021). Morphine inhibits
IL-23 signaling via Toll-like receptor 2-dependent disruption of host defenses against
infection (J. Wang, Ma, Charboneau, Barke, & Roy, 2011). Additionally, in vitro infection
of T-cells with HIV blocks IL-23 signaling, even in cells isolated from patients on highly
activate anti-retroviral therapy (Fernandes, Berthoud, Kumar, & Angel, 2017). Fernandes
et al. suggest that anti-retroviral therapy is incapable to reactivate IL-23 signaling in Tcells in vitro could influence immune activation in PLWH despite minimal viral replication
from cART treatment.
Persistent HIV-mediated inflammation both systemically (Deeks, Tracy, & Douek,
2013) and in the brain (McArthur & Johnson, 2020), in addition to aging-induced
inflammation, prompted us to investigate cytokine and chemokine levels by age. While
we saw an expected increase in mean cytokine levels in the striatum of Tat− mice, we
surprisingly saw that Tat+ mice showed a slight decrease in cytokines from 4 to 6 months
in age. We hypothesize that chronic low levels of inflammatory signaling in Tat-transgenic
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mice could be preventing any age-related vamping of inflammation levels as the basal
level of mean cytokine concentrations is higher in Tat+ compared to Tat- mice. Contrary
to cytokines, we saw a decrease in mean chemokine concentrations from 4 to 6 months
in age. Additionally, we saw that Eotaxin (CCL11) was the only chemokine individually
altered where concentrations were increased in morphine treated mice that were Tat- but
decreased in morphine treated mice that were Tat+. Eotaxin released from activated
astrocytes promotes neuronal death through its receptor CCR3 (can also bind CCR2 and
CCR5) on microglia, in turn leading to oxidative stress and glutamate-mediated
neurotoxicity (Parajuli, Horiuchi, Mizuno, Takeuchi, & Suzumura, 2015). Further
investigating microglial activation and inflammatory signaling could uncover more about
the role of cytokines and chemokines Tat ± morphine mediated neurodegeneration as
well as the connection between inflammation and KCC2 signaling.
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Figure 5. Standard curves and bead gating for LEGENDplex Inflammation Panel.
Standard curves were plotted by measured standard concentration and mean
fluorescence intensity (MFI) for each analyte (A). Representative bead scatter plot
showing gating of A and B bead populations (B). Histogram of analyte density detected
by A and B beads showing 13 populations represented by individual peaks for each
cytokine (C,D).
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Figure 6. Morphine administration increases levels of pro-inflammatory cytokines
IL-23 and IFN-β. A main effect of morphine was detected for both IL-23 (A) and IFN-β
(B) cytokine concentrations (3-way ANOVA, *p < 0.05, n = 5). Fisher’s LSD Post-hoc
analysis show that in Tat+ mice administered CLP290, IFN-β concentrations were higher
compared to Tat+ mice administered vehicle (p < 0.05) (B).
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Figure 7. Age related alterations to cytokine levels are altered by Tat expression. 2way ANOVA shows main effects of age and genotype (2-way ANOVA, age, **p < 0.01;
genotype, ***p < 0.001, n = 13/group). Post-hoc analysis reveals mean cytokine
concentrations increase with age in Tat- mice, while showing a decrease with age in Tat+
mice. Tat+ mice show an elevated mean concentration of cytokines at 4 months
compared to Tat- mice (** p < 0.01) (A). Mean levels of cytokines increase stepwise from
4 to 6 months in age in Tat- mice (* p < 0.05) (B) while decrease from 4 to 6 months in
Tat+ mice (* p < 0.05). (C).
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Figure 8. Age and genotype related alteration to cytokine levels show same trends
when split into CLP290 and morphine treatment groups. Mean cytokine
concentrations were visualized by genotype and per treatment group. When split between
morphine and CLP290 groups, cytokine values show similar trends when visualized
(increase in Tat-, decrease in Tat+), suggesting so influence of morphine or KCC2 on this
observation. Smoothened trend lines are solid for pro-inflammatory cytokines and dotted
for anti-inflammatory cytokines.
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Figure 9. Standard curves and bead gating for LEGENDplex Proinflammatory
Chemokine Panel. Standard curves were plotted by measured standard concentration
and mean fluorescence intensity (MFI) for each analyte (A). Representative bead scatter
plot showing gating of A and B bead populations (B). Histogram of analyte density
detected by A and B beads showing 13 populations represented by individual peaks for
each chemokine (C,D).
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Figure 10. Only Eotaxin (CCL11) is altered by morphine but depends on Tat
expression. Eotaxin concentrations were increased in morphine treated animals that
were Tat-, but were decreased in animals that were Tat+ (Genotype x Morphine
interaction, p < 0.05, n = 5) (A). No significant differences were detected for the
chemokines CCL3, CCL4, IP-10, or BLC (B-E).
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Figure 11. Mean chemokine concentrations lower with age. 2-way ANOVA shows a
main effect of age (2-way ANOVA, age, p < 0.05; genotype, n = 5/group). Post-hoc
analysis reveals mean chemo concentrations decrease with age from 4 to 6 months in
age in both Tat- and Tat+ mice (** p < 0.01) (A). Mean levels of chemokines decrease
from 4 months compared to 6 months in age in Tat- and Tat+ mice (* p < 0.05) (B, C).
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Chapter 5: Conclusions and Future Directions
The Tat-transgenic mouse model enabled us to study the in vivo role of KCC2 in
Tat ± morphine induced neurodegeneration. In vivo Tat-expression has been shown to
induce anxiety-like behavior and hyperactivity in male mice. We sought to see if these
results were the same in female mice and enhance these studies with morphine cotreatment along with CLP290 administration to understand the role of KCC2. Interestingly,
we found no effect of Tat expression on behavioral outcomes in an open field task but did
see a major effect morphine leading to decreased exploratory behavior and increased
anxiety like behavior. These results were not due to locomotor impairment as all groups
had similar distance traveled in the open field and performed similarly on a rotarod task.
Following behavioral testing, we wanted to investigate molecular changes in the
striatum that could be tied to our behavioral results by western blot analysis. While the
striatum is classically known for its role in locomotion via the direct and indirect pathways
(Fieblinger, 2021), striatal circuitry is also implicated in anxiety and depression
(Macpherson & Hikida, 2019; Quarmley, Nelson, Clarkson, White, & Jarcho, 2019). We
found CLP290 increased overall levels of KCC2 but not pS940-KCC2 or NKCC1.
Although the behavioral results did not coincide with Tat and/or morphine-dependent
changes in levels of pS940-KCC2 or total KCC2 and we unaffected by CLP290 in female
mice, we found Tat-expressing mice showed lower levels of TMEM16a and CLP290
lowered TMEM16a levels overall. We focused on the striatum specifically as previous
studies in male mice showed region specific loss of KCC2 within the striatum (Barbour et
al., 2021). Further investigation into KCC2 within more specific anxiety related brain
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regions such as the amygdala and prefrontal cortex may lead to a better understanding
of molecular changes connected to our behavioral results.
We designed our behavioral studies to attempt to observe the effects of morphine
and any potential interaction with Tat and CLP290. Accordingly, tests were conducted 1hour following a 40 mg/kg morphine injection. To examine the acute effects of morphine,
while avoiding the effects of physical withdrawal, we chose our 1-hour timepoint. Most
studies examining spontaneous morphine withdrawal wait at least 5 hours after the final
injection (Ayoub et al., 2021; Papaleo & Contarino, 2006; Quock & Brewer, 2019), since
the half-life of morphine in wildtype mice is typically less than 60 minutes (Zelcer et al.,
2005). While we assessed behavior close to the final injection time, it is still possible that
the mice are undergoing signs of somatic withdrawal or withdrawal events at the
molecular level which could be having an impact on behavior. Thus, a better
understanding of the temporal window for morphine effects and morphine withdrawal in
our mice is needed and how Tat may interfere with pharmacodynamics of morphine. For
example, Fitting et al. found that 2-week Tat induction reduces the antinociceptive efficacy
of 8 mg/kg morphine administration in a tail flick assay 20 minutes post-final injection
(Fitting et al., 2016). A more acute time course of withdrawal effects from morphine such
as wet dog shakes, jumping, and paw tremors at 20, 40, 60, and 120 minutes in both Tatand Tat+ mice would be beneficial to ensure behavioral testing is done before any somatic
withdrawal signs appear. Additionally, molecular changes in the brain such as increased
phosphorylation of cAMP-response element binding protein and c-fos expression could
be used as markers in these further studies or on the animals in these studies to assess
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morphine withdrawal (Chan & Lutfy, 2016; Georges, Stinus, & Le Moine, 2000; Martín,
Laorden, & Milanés, 2009).
Previous studies in Tat-transgenic mice have found that KCC2 levels as well as
phosphorylation at S940 are decreased following two weeks of Tat expression and these
changes are reversed with CLP290 (Barbour et al., 2020, 2021). While our results support
CLP290 increasing KCC2 immunoreactivity, we see no changes in KCC2 levels in Tatexpressing mice nor in phosphorylation at S940. The main difference between our results
and previous findings is our studies were performed in female rather than male mice.
Perrot-Sinal et al. have shown that there are sex differences in the expression of both
NKCC1 and KCC2 in the developing hypothalamus (Perrot-Sinal, Sinal, Reader, Speert,
& McCarthy, 2007). Additionally, in situ hybridization studies have shown KCC2 mRNA
expression is higher in females than males irrespective of age in the substantia nigra pars
reticulata (Galanopoulou, Kyrozis, Claudio, Stanton, & Moshé, 2003). Higher expression
at the mRNA level in females could compensate for any potential slc12a gene expression
downregulation by Tat. These findings remain true at the protein level as KCC2
immunoreactivity in the mediobasal hypothalamus of female rats is significantly higher
than in males (Perrot-Sinal, Sinal, Reader, Speert, & Mccarthy, 2007). Unfortunately, all
studies are performed during the perinatal period and no insights into potential sex
differences during adulthood have been found. Further investigation with both males and
females within the same experimental cohort and identical treatment paradigm is
necessary to definitively determine if there is a sex difference in KCC2 regulation and
effects from Tat ± morphine.
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Surprisingly, LEGENDplex analysis of cytokines and chemokines in the striatum
did not reveal major changes to individual analytes following Tat ± morphine exposure.
Both Tat ± morphine have been shown to induce alterations in cytokine and chemokine
levels both in vitro (El-Hage et al., 2008, 2005) and in vivo (Gonek et al., 2018; Hermes
et al., 2020; Nass et al., 2020). Additionally, cytokine and chemokine release is extremely
dynamic and can depend on the type of insult, duration of treatment, or even time of day
(Nakao, 2014; Tweedie et al., 2020). We collected brain samples following 2-weeks of
Tat induction and morphine administration, it is possible that cytokine and chemokine
levels were elevated initially but declined due to tolerance of from chronically activated
signaling (Gillen et al., 2021). Possible ways we could combat this in the future is to collect
serum from the mice and analyze systemic inflammation versus a specific brain region or
assess changes to inflammatory markers at the gene level. Cytokine and chemokines
have very short half-lives (Aziz et al., 2016; Lotze et al., 1985) and due to their instability,
then can be difficult to detect. Collecting mRNA and running quantitative PCR could give
a more accurate insight into the inflammatory markers and signaling pathways being
activated.

Final Conclusions: This work sought out to understand the role of KCC2 on Tat ±
morphine induced neurodegeneration in female mice through administration of the KCC2
enhancing pro-drug CLP290. We identified that a 2-week ramping dose of morphine led
to anxiety-like behavior and decreased exploration. Using striatal protein lysates from
these mice, we saw CLP290 increased levels of KCC2 but had no effect on pS940-KCC2,
suggesting a potential alternative mechanism through which CLP290 can regulate KCC2.
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Additionally, we saw a Tat mediated decrease in immunoreactivity of the CaCC
TMEM16a and a main effect of CLP290 on TMEM16a. As both TMEM16a and KCC2
regulate Cl-, modulation of KCC2 could be impacting function and expression of
TMEM16a. Lastly, the studies in Chapter 4 described how cytokine and chemokine levels
in the striatum of these mice showed differential trends depending on age and genotype.
Additionally, we saw alteration to concentrations of IL-23, IFN-b, and Eotaxin (CCL-11)
providing potential insight into activated signaling pathways. Overall, these studies give
insight into the need to perform identical studies using males and females to investigate
potential sex differences of Tat and or morphine on KCC2 regulation, spontaneous
locomotion, and anxiety as well as sex-specific changes to inflammatory signaling.
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